Adagio names David Hering as permanent CEO and Director

Jul. 05, 2022 7:34 AM ETInvivyd, Inc. (IVVD)By: Niloofer Shaikh, SA News Editor1 Comment
  • Adagio Therapeutics (NASDAQ:ADGI) has named interim chief executive officer and chief operating officer David Hering, as company’s permanent CEO and a director on the board.
  • “As COVID-19 continues to infect millions worldwide, we are committed to the ongoing advancement of Adagio’s founding mission focused on delivering both treatment and prophylactic solutions for COVID-19 and other important infectious diseases,” said Marc Elia, chair of Adagio’s Board of Directors. “A thorough process underlined Dave’s core skills and deep expertise. He is the ideal person to lead Adagio through its next phase of growth, and we are thrilled to appoint him as CEO and director. We believe Adagio has best-in-class antibody discovery and development capabilities and to fully realize its potential the company requires leadership with substantial operational and commercial experience. Dave has a unique track record leading organizations focused on infectious disease medicines, including the launch of the first and market leading COVID-19 vaccine during his time at Pfizer. We are excited about the road ahead for Adagio and the impact we may have on people in need.”
  • Shares down 3.4% PM.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.